Medicines and Vehicle Crashes

Abstract

Abstract: Medicines that have known effects on the central nervous system, blood glucose levels, blood pressure, vision, or otherwise have the potential to interfere with driving skills have been termed "potentially driver-impairing" (PDI). These mcdicines include CNS depressants, antihistamine, antihypertensive drugs, hypoglycemics, pain relievers etc. PDI effects include sedation, drowsiness, dizziness, hypotension, hypoglycemia, blurred vision and loss of coordination. It is important to increase awareness among health care providers and drivers regarding the potential driver impairing effects of pharmaceutical use.

Key words: medicines, potentially driver-impairing, vehicle crashes

ZHOU Mi-mei, GUO Mei, YIN Li-fang. Medicines and Vehicle Crashes[J]. Chinese Journal of Pharmacovigilance, 2012, 9(3): 173-177.

References

[1] Leroy A, Morse MM, for US DOT/NHTSA. Exploratory study of?the relationship between multiple medications and vehicle?crashes. Was-hington,DC:U.S.DOT/NHTSA;2008[EB/OL].http://www.nhtsa.gov/DOT/NHTSA/810858.pdf. Accessed December 4, 2010.
[2] Couper FJ, Logan BK for US DOT/NHTSA.Drugs and human performance fact sheets.Washington,DC:2004[EB/OL].http://www.nhtsa.dot.gov/people/injury/drugs_web.pdf.Accessed December 4, 2010.
[3] Thomson Healthcare eds. Donnatal Extentabs prescribing information. In: Physicians' Desk Reference[M]. 2009. 63d ed. New York, NY: Thomson Reuters, 2009:2507.
[4] Stefanacci RG, Cavallaro E, Beers MH, et al. Developing explicit positive beers criteria for preferred central nervous system medications in older adults[J]. Consult Pharm. 2009;24:601-610.
[5] Hebert C, Delaney JA, Hemmelgarn B,et al. Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs[J]. Pharmacoepidemiol Drug Saf. 2007;16:845-849.
[6] Meskali M, Berthelon C, Marie S, et al. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study[J]. Psychopharmacology.2009; 207(3):461-467.
[7] Ramaekers J. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test[J]. J Clin Psychiatry. 2003;64:20-29.
[8] Fluoxetine hydrochloride. US FDA, CDER website. Rockaway, NJ: Eli Lilly and Company[EB/OL]. May 4, 2009. http://www.accessdata.fda.gov/drugsatfda_docs.Accessed December 14, 2009.
[9] Trazodone hydrochloride. Princeton, NJ: Bristol-Myers Squibb[EB/OL]. February 2009. http://packageinserts.bms.com/pi. Accessed December 14, 2009.
[10] Venlafaxine hydrochloride. US FDA, CDER website. Philadelphia, Pa: Wyeth Pharmaceuticals[EB/OL].November, 2008. http://www.wyeth.com/content. Accessed December 10, 2010.

[1]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[2]	SHEN Pan, SUN Dezhi, ZHOU Wei, GAO Yue. Research progress in toxicity prediction of traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 473-479.
[3]	JIANG Jiandong. Development and clinical safety of paediatric medicines in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
[4]	WANG Zhonglan, WANG Yu, HAO Lina, HU Lihua, WANG Xiaoling, ZHAO Zhigang. Taking wrong medicines by children and precautions [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 779-781.
[5]	YU Hongli, PANG Yu, SHAO Bo, XIAO Aili, YU Dongmei. Current Adverse Drug Reaction Reporting and Monitoring of Essential Medicines in China [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768.
[6]	WU Hao, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng. Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines [J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 406-410.
[7]	ZHU Xueyan. Research and Application Progress of Two-dimentional Liquid Chromatography on Quality Control for Traditional Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 643-646.
[8]	ZHU Lan, Shao Bo, XIA Dongsheng. Selection and Switch-to-OTC of Chinese Patent Medicines in China [J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
[9]	WANG Tao, WANG Dan, FAN Yan, DONG Duo. Upgrade of EudraVigilance in the EU and Its Considerations [J]. Chinese Journal of Pharmacovigilance, 2018, 15(7): 411-413.
[10]	WU Nan, YANG Yue. Inspiration from EU EndraVigilance [J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 230-233.
[11]	LU Jing, ZHEN Jian-cun. Analysis of Inpatient Medical Prescriptions of Oral Medicines between 2013 and 2016 [J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 113-115.
[12]	WANG Pei-jie, WANG Jia-lun, YI Zhi-wei, Dong Yan-fei, WANG Pu. Literature Analysis of 40 Cases of Adverse Drug Reactions of Nonprescription Chinese Patent Medicines for Diseases of Throat Department [J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 690-692.
[13]	LIU Cui-li, XIA Dong-sheng. Discussion on the Monitoring of the Adverse Reaction and the Risk Management of Essential Medicines [J]. Chinese Journal of Pharmacovigilance, 2014, 11(10): 614-617.
[14]	MA Ping, LI Peng-fei ,CAO Miao, DING Chun-lei ,WANG Yan, LIU Li-hong. High Throughput and Rapid Screening for Illegally Added Chemicals in Chinese Patent Medicines and Health Products by LC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 19-21.
[15]	XIAO Ai-li, YAN Lin, JING Chun-mei. Field Research on the Disease Coverage of "National Essential Medicines List" [J]. Chinese Journal of Pharmacovigilance, 2012, 9(7): 401-409.